Quick Answer
NewAmsterdam Pharma Co N.V. reported Diluted EPS of $1.72 per share (loss) for fiscal year 2025.
NewAmsterdam Pharma Co N.V. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$1.72 | +32.8% |
| 2024 | -$2.56 | -19.1% |
| 2023 | -$2.15 | -80.7% |
| 2022 | -$1.19 | +68.8% |
| 2021 | -$3.81 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.61 | -238.9% | -306.7% |
| June 30, 2025 | -$0.15 | +63.4% | +55.9% |
| March 31, 2025 | -$0.34 | +67.9% | -88.9% |
| September 30, 2024 | -$0.18 | +68.4% | +56.1% |
| June 30, 2024 | -$0.41 | +12.8% | +61.3% |
| March 31, 2024 | -$1.06 | -107.8% | -86.0% |
| September 30, 2023 | -$0.57 | — | -21.3% |
| June 30, 2023 | -$0.47 | — | +7.8% |
- NewAmsterdam Pharma Co N.V. showed an increase of +32.8% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2025 period, NewAmsterdam Pharma Co N.V.’s diluted eps has grown by 54.9% (from $3.81 per share (loss) to $1.72 per share (loss)).
- The most recent figure is from NewAmsterdam Pharma Co N.V.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 18, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: